Galderma will acquire ZO Skin Health from Blackstone and the Obagi family for $1.5 billion, according to the deal announcement tracked by Pulse 2.0.

The transaction hands Galderma one of the better-known names in physician-dispensed skincare. ZO Skin Health was founded by dermatologic surgeon Dr. Zein Obagi, whose eponymous brand built its reputation on medical-grade formulations sold chiefly through dermatology and aesthetics practices.

The sellers are two parties: private equity firm Blackstone, which held a controlling stake, and the Obagi family, which retained ownership alongside the investor. The $1.5 billion price covers the full buyout of both positions.

Why does Galderma want ZO?

For Galderma, the purchase extends a portfolio that already spans injectable, therapeutic and consumer dermatology lines. Physician-dispensed skincare has become a strategic target for dermatology conglomerates because it anchors the medical-aesthetics channel — the same practices that deliver injectables and energy-based treatments.

The structure of the deal mirrors a familiar pattern. Private equity firm Blackstone took its position in ZO Skin Health years ago, held it through a period of brand expansion, and is now exiting at a headline valuation of $1.5 billion. The Obagi family cashes out its remaining share in the same transaction.

What does the price signal?

A $1.5 billion consideration places ZO Skin Health among the more valuable standalone skincare assets to change hands recently. The figure reflects both the brand's distribution through medical channels and the premium that consolidated dermatology platforms command from strategic buyers.

For dermatology practices, the immediate practical question is continuity: physician-dispensed product lines rarely change formulation or distribution after acquisitions of this kind, but practice managers will watch Galderma's integration plans for any shifts in pricing, ordering or professional support programs.

Neither the announcement tracked by Pulse 2.0 nor the parties involved have detailed the expected closing timeline or regulatory conditions, and no revenue or growth figures for ZO Skin Health accompanied the deal headline.

Assuming the transaction closes as announced, Galderma adds a founder-led, practice-anchored skincare brand to its roster — and the medical-grade skincare market gets its clearest valuation benchmark in years.